for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Synlogic Inc

SYBX.OQ

Latest Trade

2.17USD

Change

0.00(0.00%)

Volume

23,569

Today's Range

2.12

 - 

2.19

52 Week Range

1.96

 - 

11.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Synlogic Announces Appointments Of New CMO, Head Of Regulatory Affairs, And CFO Departure

Sept 4 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC ANNOUNCES APPOINTMENTS OF NEW CMO, HEAD OF REGULATORY AFFAIRS, AND CFO DEPARTURE.SYNLOGIC INC - DEPARTURE OF TODD SHEGOG, CHIEF FINANCIAL OFFICER, EFFECTIVE SEPTEMBER 18.SYNLOGIC INC - COMMENCED A SEARCH FOR A NEW CFO.SYNLOGIC INC - TODD SHEGOG LEAVING COMPANY TO PURSUE ANOTHER OPPORTUNITY.

Synlogic Says Selling Stockholder May Offer And Resell Under This Prospectus Of Up To 8.9 Mln Shares Of Co's Common Stock

Aug 8 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC INC - SELLING STOCKHOLDER MAY OFFER AND RESELL UNDER THIS PROSPECTUS OF UP TO 8.9 MILLION SHARES OF COS' COMMON STOCK - SEC FILING.

Synlogic Q2 Loss Per Share $0.45

Aug 8 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES PROGRAM UPDATES.Q2 LOSS PER SHARE $0.45.Q2 REVENUE $400,000 VERSUS $300,000.Q2 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.Q2 REVENUE ESTIMATE $733,000 -- REFINITIV IBES DATA.

Synlogic Expects To Initiate SYNB1618 Efficacy Study In First Half Of 2020

July 15 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC REPORTS POSITIVE TOP-LINE DATA FROM PHASE 1/2A STUDY OF SYNB1618 IN PATIENTS WITH PHENYLKETONURIA AND GUIDES TO NEXT PHASE OF DEVELOPMENT.SYNLOGIC INC - DATA DEMONSTRATE STATISTICALLY SIGNIFICANT BIOMARKER ACTIVITY AT WELL-TOLERATED DOSE IN PKU PATIENTS.SYNLOGIC INC - PLAN TO INITIATE BRIDGING STUDY WITH NEW ORAL SOLID FORMULATION IN Q3 2019.SYNLOGIC INC - EXPECTS TO INITIATE SYNB1618 EFFICACY STUDY IN FIRST HALF OF 2020..

Synlogic And Ginkgo Bioworks Establish Platform Collaboration

June 12 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC AND GINKGO BIOWORKS ESTABLISH TRANSFORMATIONAL PLATFORM COLLABORATION FOR THE ACCELERATED DEVELOPMENT OF NOVEL SYNTHETIC BIOTIC™ MEDICINES.SYNLOGIC- AGREEMENT PROVIDES $80.0 MILLION EQUITY INVESTMENT AT A PREMIUM IN SYNLOGIC BY GINKGO AND ENTRY INTO LONG-TERM STRATEGIC PLATFORM COLLABORATION.SYNLOGIC-HAS EXCLUSIVE RIGHTS TO ANY SYNTHETIC BIOTIC MEDICINES IT DEVELOPS AS PART OF COLLABORATION & TO INTELLECTUAL PROPERTY COVERING SUCH PRODUCTS.

Synlogic Announces Collaboration To Evaluate Synb1891 In Combination With Pd-L1 In Patients With Advanced Solid Tumors

May 22 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC ANNOUNCES CLINICAL COLLABORATION TO EVALUATE SYNB1891 IN COMBINATION WITH PD-L1 CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS.SYNLOGIC - COLLABORATION WITH ROCHE TO EXPLORE CO'S SYNTHETIC BIOTIC MEDICINE, SYNB1891 IN COMBINATION WITH ROCHE'S PD-L1-BLOCKING CHECKPOINT INHIBITOR ATEZOLIZUMAB.SYNLOGIC INC - EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION WITH FDA IN SECOND HALF OF 2019 FOR SYNB1891.

Synlogic Reports Fourth Quarter And Full Year 2018 Financial Results

March 12 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.47.Q4 EARNINGS PER SHARE ESTIMATE $-0.54 -- REFINITIV IBES DATA.Q4 REVENUE $100,000.Q4 REVENUE ESTIMATE $214,000 -- REFINITIV IBES DATA.ENDED 2018 WITH APPROXIMATELY $123 MILLION IN CASH AND INVESTMENTS, WHICH PROVIDES RUNWAY THROUGH 2020.CLINICAL TRIAL READOUTS EXPECTED IN MID-2019 FROM 2 SYNTHETIC BIOTIC MEDICINES.FIRST IND APPLICATION EXPECTED FROM SYNLOGIC'S IMMUNO-ONCOLOGY PLATFORM IN SECOND HALF OF 2019.

Synlogic Inc - Investigational New Drug Application For SYNB1891 Expected In 2H2019

Jan 3 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC INC - PRESENTATION OF TOPLINE CLINICAL DATA FROM STUDIES OF SYNTHETIC BIOTIC MEDICINES, SYNB1020 AND SYNB1618, IN PATIENTS EXPECTED MID-2019.SYNLOGIC INC - INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR SYNB1891, SYNLOGIC'S FIRST IMMUNO-ONCOLOGY PROGRAM, EXPECTED IN 2H2019.

Synlogic Reports Q3 Loss Per Share $0.43

Nov 13 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PROGRAM UPDATES.Q3 LOSS PER SHARE $0.43.Q3 REVENUE $1.8 MILLION VERSUS $100,000.Q3 REVENUE VIEW $204,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.

Synlogic - Reports Positive Interim Phase 1/2A Data For Synb1618

Sept 4 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC - REPORTS POSITIVE INTERIM PHASE 1/2A DATA DEMONSTRATING SAFETY, TOLERABILITY & PROOF-OF-MECHANISM IN HEALTHY VOLUNTEERS FOR SYNB1618.SYNLOGIC-DATA SHOWS STATISTICALLY SIGNIFICANT DOSE-DEPENDENT EFFECTS ON SYNB1618 ACTIVITY-ASSOCIATED BIOMARKERS, SUPPORTS FURTHER DEVELOPING SYNB1618.SYNLOGIC-SYNB1618 DOSE ESTABLISHED FOR TREATMENT ARM OF ONGOING PHASE 1/2A STUDY IN PATIENTS WITH PHENYLKETONURIA; TOP-LINE DATA EXPECTED IN MID-2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up